Avonex

Bloomberg Businessweek (Asia) - - FOCUS ON / PHARMA -

Bio­gen has been ratch­et­ing down dis­counts on Avonex as de­mand de­clines and it fo­cuses on its newer mul­ti­ple scle­ro­sis medicines. The re­sult: The af­ter­dis­count price has more than tripled in six years.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.